Prelude Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-5,317
| Closed | -$288K | – | 1309 |
|
|
2025
Q3 | $288K | Buy |
+5,317
| New | +$304K | 0.02% | 751 |
|
|
2023
Q3 | – | Sell |
-15,282
| Closed | -$1.32M | – | 1145 |
|
|
2023
Q2 | $1.32M | Buy |
15,282
+554
| +4% | +$52.1K | 0.09% | 263 |
|
|
2023
Q1 | $1.43M | Buy |
14,728
+64
| +0.4% | +$6.63K | 0.09% | 263 |
|
|
2022
Q4 | $1.52M | Buy |
14,664
+11,052
| +306% | +$1.04M | 0.08% | 270 |
|
|
2022
Q3 | $306K | Sell |
3,612
-6,170
| -63% | -$549K | 0.01% | 857 |
|
|
2022
Q2 | $811K | Buy |
+9,782
| New | +$779K | 0.02% | 604 |
|
|
2021
Q1 | – | Sell |
-7,105
| Closed | -$623K | – | 1545 |
|
|
2020
Q4 | $623K | Buy |
+7,105
| New | +$563K | 0.02% | 640 |
|
|
2020
Q3 | – | Sell |
-4,177
| Closed | -$423K | – | 1844 |
|
|
2020
Q2 | $515K | Buy |
4,177
+1,209
| +41% | +$120K | 0.03% | 467 |
|
|
2020
Q1 | $251K | Sell |
2,968
-6,772
| -70% | -$584K | 0.02% | 408 |
|
|
2019
Q4 | $824K | Buy |
9,740
+9,657
| +11,635% | +$729K | 0.03% | 444 |
|
|
2019
Q3 | $6K | Sell |
83
-11,550
| -99% | -$890K | ﹤0.01% | 1541 |
|
|
2019
Q2 | $996K | Buy |
11,633
+6,787
| +140% | +$581K | 0.05% | 344 |
|
|
2019
Q1 | $430K | Buy |
4,846
+1,200
| +33% | +$111K | 0.02% | 530 |
|
|
2018
Q4 | $310K | Sell |
3,646
-3,491
| -49% | -$332K | 0.02% | 601 |
|
|
2018
Q3 | $692K | Buy |
7,137
+2,758
| +63% | +$275K | 0.04% | 446 |
|
|
2018
Q2 | $413K | Buy |
4,379
+95
| +2% | +$8.32K | 0.03% | 586 |
|
|
2018
Q1 | $347K | Sell |
4,284
-5,952
| -58% | -$511K | 0.03% | 535 |
|
|
2017
Q4 | $913K | Buy |
10,236
+7,742
| +310% | +$673K | 0.07% | 275 |
|
|
2017
Q3 | $232K | Sell |
2,494
-2,781
| -53% | -$246K | 0.02% | 596 |
|
|
2017
Q2 | $479K | Buy |
+5,275
| New | +$480K | 0.05% | 338 |
|
|
2017
Q1 | – | Sell |
-2,903
| Closed | -$258K | – | 1505 |
|
|
2016
Q4 | $240K | Buy |
2,903
+872
| +43% | +$75K | 0.03% | 511 |
|
|
2016
Q3 | $188K | Sell |
2,031
-2,938
| -59% | -$277K | 0.02% | 587 |
|
|
2016
Q2 | $387K | Sell |
4,969
-1,396
| -22% | -$119K | 0.05% | 333 |
|
|
2016
Q1 | $525K | Sell |
6,365
-3,756
| -37% | -$306K | 0.07% | 297 |
|
|
2015
Q4 | $1.06M | Buy |
10,121
+1,494
| +17% | +$156K | 0.16% | 146 |
|
|
2015
Q3 | $909K | Sell |
8,627
-963
| -10% | -$129K | 0.13% | 186 |
|
|
2015
Q2 | $1.31M | Sell |
9,590
-725
| -7% | -$89.8K | 0.18% | 145 |
|
|
2015
Q1 | $1.28M | Buy |
10,315
+6,471
| +168% | +$686K | 0.18% | 146 |
|
|
2014
Q4 | $347K | Sell |
3,844
-1,330
| -26% | -$111K | 0.05% | 433 |
|
|
2014
Q3 | $373K | Buy |
5,174
+1,147
| +28% | +$75.4K | 0.05% | 482 |
|
|
2014
Q2 | $251K | Sell |
4,027
-4,091
| -50% | -$247K | 0.03% | 653 |
|
|
2014
Q1 | $554K | Buy |
8,118
+3,062
| +61% | +$226K | 0.07% | 358 |
|
|
2013
Q4 | $356K | Hold |
5,056
| – | – | 0.06% | 463 |
|
|
2013
Q3 | $365K | Sell |
5,056
-7,665
| -60% | -$509K | 0.06% | 372 |
|
|
2013
Q2 | $709K | Buy |
+12,721
| New | +$793K | 0.15% | 172 |
|
Other funds holding BMRN
Prelude Capital Management's BMRN Position: Q4 2025 in Review
Prelude Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 5,317 shares — an estimated $288K sold.
Prelude Capital Management first reported a position in BMRN in Q2 2013 and held it in 35 quarters. The position peaked at $1.52M in Q4 2022. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Prelude Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Prelude Capital Management sold 5,317 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $288K.
- Prelude Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 35 quarters.
- Prelude Capital Management's BioMarin Pharmaceuticals position peaked at $1.52M in Q4 2022.
- 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.